Bassoulet J, Pabot du Chatelard P, Ricordel I, Auberget J L, Guillemot M C, Merrer J, Timbal Y
Service de Radiothérapie Oncologique, Hôpital d'instruction des armées du Val-de-Grâce, Paris.
J Urol (Paris). 1988;94(8):393-6.
Between 1978 and 1985, 128 patients with germinal tumors of the testes were treated at the Val-de-Grâce Hospital; biological market levels--beta HCG and AFP--were determined before and after orchidectomy in the peripheral blood and during orchidectomy in testicular blood in 76 patients. HCG levels were elevated in 13% of seminomas and HCG and/or AFP levels were elevated in 76% of non seminomas; the sensitivity of the determination was greater in testicular blood. However, in our study, there was no parallelism between marker levels before orchidectomy and tumor stage or prognosis. The change in HCG and/or AFP levels appears to an index of the response to therapy: 4 patients with high HCG and/or AFP levels during chemotherapy died. The diagnosis of recurrence is not always documented by elevated marker levels and monitoring must always documented by elevated marker levels and monitoring must always include both determination of marker levels and imaging.
1978年至1985年间,瓦尔-德-格拉斯医院收治了128例睾丸生殖细胞瘤患者;对76例患者在睾丸切除术前、术后外周血以及睾丸切除术中睾丸血中测定了生物学标志物水平——β-HCG和AFP。13%的精原细胞瘤患者HCG水平升高,76%的非精原细胞瘤患者HCG和/或AFP水平升高;睾丸血中测定的敏感性更高。然而,在我们的研究中,睾丸切除术前标志物水平与肿瘤分期或预后之间没有相关性。HCG和/或AFP水平的变化似乎是治疗反应的一个指标:4例化疗期间HCG和/或AFP水平高的患者死亡。复发的诊断并不总是通过标志物水平升高来证实,监测必须始终包括标志物水平测定和影像学检查,且标志物水平升高时必须记录在案。